Xoma notes FDA approval of Zevra’s MIPLYFFA in patients with NPC

XOMA Royalty Corporation (XOMA) announced Zevra Therapeutics (ZVRA) has received approval from the U.S. Food and Drug Administration for MIPLYFFA. MIPLYFFA is approved for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C in adult and pediatric patients two years of age and older. It is the sixth commercial asset in XOMA Royalty’s growing royalty and milestone portfolio. In June 2023, XOMA Royalty announced it had paid LadRx a $5 million upfront payment plus a share of future event-based milestones to acquire a mid-single digit royalty on arimoclomol’s commercial sales and up to $52.6 million, net, in potential milestone payments from Zevra.